Targeted nonviral gene-based inhibition of Gα(i/o)-mediated vagal signaling in the posterior left atrium decreases vagal-induced atrial fibrillation.

@article{Aistrup2011TargetedNG,
  title={Targeted nonviral gene-based inhibition of Gα(i/o)-mediated vagal signaling in the posterior left atrium decreases vagal-induced atrial fibrillation.},
  author={Gary L. Aistrup and Ivan Cokic and Jason Ng and David Gordon and Hemanth Koduri and Suzanne Browne and Dorina Arapi and Yogita Segon and Jacob Goldstein and Abigail Angulo and John Andrew Wasserstrom and Jeffrey J. Goldberger and Alan H. Kadish and Rishi Arora},
  journal={Heart rhythm},
  year={2011},
  volume={8 11},
  pages={1722-9}
}
BACKGROUND Pharmacologic and ablative therapies for atrial fibrillation (AF) have suboptimal efficacy. Newer gene-based approaches that target specific mechanisms underlying AF are likely to be more efficacious in treating AF. Parasympathetic signaling appears to be an important contributor to AF substrate. OBJECTIVE The purpose of this study was to develop a nonviral gene-based strategy to selectively inhibit vagal signaling in the left atrium and thereby suppress vagal-induced AF. METHODS… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Improving Atrial Fibrillation Therapy: Is There a Gene for That?

Journal of the American College of Cardiology • 2017
View 3 Excerpts
Highly Influenced

Clinical Effects of “Selective Drug” Regulating Vagus Nerve Signal Pathway in Vagally-Mediated Atrial Fibrillation

Medical science monitor : international medical journal of experimental and clinical research • 2018
View 1 Excerpt

Biological Therapies for Atrial Fibrillation: Ready for Prime Time?

Journal of cardiovascular pharmacology • 2016
View 2 Excerpts

Similar Papers

Loading similar papers…